MA27837A1 - Beta-carbolines utiles pour traiter une maladie inflammatoire. - Google Patents

Beta-carbolines utiles pour traiter une maladie inflammatoire.

Info

Publication number
MA27837A1
MA27837A1 MA28592A MA28592A MA27837A1 MA 27837 A1 MA27837 A1 MA 27837A1 MA 28592 A MA28592 A MA 28592A MA 28592 A MA28592 A MA 28592A MA 27837 A1 MA27837 A1 MA 27837A1
Authority
MA
Morocco
Prior art keywords
inflammatory disease
treating inflammatory
useful
beta carbolines
beta
Prior art date
Application number
MA28592A
Other languages
English (en)
French (fr)
Inventor
Michael E Hepperle
Julie Fields Liu
Francois Soucy
Yingchun Ye
Robert S Murray
Raman Prakash
Jeremy D Little
Alfredo Castro
Hormoz Mazdiyasni
Paul E Fleming
Dominic Reynolds
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA27837A1 publication Critical patent/MA27837A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA28592A 2003-04-09 2005-11-09 Beta-carbolines utiles pour traiter une maladie inflammatoire. MA27837A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09

Publications (1)

Publication Number Publication Date
MA27837A1 true MA27837A1 (fr) 2006-04-03

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28592A MA27837A1 (fr) 2003-04-09 2005-11-09 Beta-carbolines utiles pour traiter une maladie inflammatoire.

Country Status (22)

Country Link
US (2) US7727985B2 (enExample)
EP (1) EP1611134A1 (enExample)
JP (1) JP2006522824A (enExample)
KR (1) KR20060006031A (enExample)
CN (1) CN1802375A (enExample)
AU (1) AU2004230952A1 (enExample)
BR (1) BRPI0409263A (enExample)
CA (1) CA2521300A1 (enExample)
CO (1) CO5700746A2 (enExample)
CR (1) CR8042A (enExample)
EA (1) EA009121B1 (enExample)
EC (1) ECSP056145A (enExample)
HR (1) HRP20050926A2 (enExample)
MA (1) MA27837A1 (enExample)
MX (1) MXPA05010793A (enExample)
NI (1) NI200500174A (enExample)
NO (1) NO20054598L (enExample)
OA (1) OA13115A (enExample)
RS (1) RS20050832A (enExample)
TN (1) TNSN05257A1 (enExample)
WO (1) WO2004092167A1 (enExample)
ZA (1) ZA200508198B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522824A (ja) 2003-04-09 2006-10-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患を処置するために有用なβ−カルボリン
BRPI0509660A (pt) * 2004-04-09 2007-10-09 Millennium Pharm Inc compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2006316322B2 (en) * 2005-11-22 2011-08-25 Merck Canada Inc. Tricyclic compounds useful as inhibitors of kinases
US8426355B2 (en) * 2006-03-15 2013-04-23 Theralogics, Inc. Methods of treating muscular wasting diseases using NF-κB activation inhibitors
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
AU2007334541A1 (en) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (AISTM's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
WO2009054970A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Mesylate salt of an ikk inhibitor
WO2009054965A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Salts of n- (6-chloro-9h-pyrido [3,4-b] ind0l-8-yl) -4- [2- (2, 6-dimethyl-4-morpholinyl) -2-0x0e thyl] -6, 6-dimethyl-morpholinecarboxamide
EP2297347B1 (en) 2008-05-14 2017-03-08 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
CN102171204B (zh) 2008-10-02 2014-08-20 旭化成制药株式会社 8位取代异喹啉衍生物及其用途
WO2011120911A1 (en) 2010-03-30 2011-10-06 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
US9440966B2 (en) * 2011-03-28 2016-09-13 Sjt Molecular Research, S.L. Compounds for treatment of metabolic syndrome
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE297908T1 (de) * 1998-08-12 2005-07-15 Pfizer Prod Inc Tace inhibitoren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
MXPA02007981A (es) 2000-03-15 2004-04-05 Aventis Pharma Gmbh Beta-carbolinas sustituidas con actividad que inhibe la ikb-cinasa.
BR0212617A (pt) * 2001-09-19 2005-02-09 Pharmacia Corp Compostos de pirazolila substituìdo para o tratamento de inflamação
AU2002352498A1 (en) * 2001-11-07 2003-05-19 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
WO2004080996A1 (en) * 2003-03-07 2004-09-23 Eli Lilly And Company Opioid receptor antagonists
JP2006522824A (ja) 2003-04-09 2006-10-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患を処置するために有用なβ−カルボリン

Also Published As

Publication number Publication date
WO2004092167A1 (en) 2004-10-28
OA13115A (en) 2006-11-10
HRP20050926A2 (en) 2006-06-30
AU2004230952A1 (en) 2004-10-28
NO20054598L (no) 2005-10-27
MXPA05010793A (es) 2005-12-05
US20100093713A1 (en) 2010-04-15
ECSP056145A (es) 2006-04-19
EP1611134A1 (en) 2006-01-04
RS20050832A (sr) 2007-12-31
US20040235839A1 (en) 2004-11-25
ZA200508198B (en) 2007-01-31
EA200501584A1 (ru) 2006-06-30
WO2004092167A8 (en) 2006-01-05
JP2006522824A (ja) 2006-10-05
EA009121B1 (ru) 2007-10-26
CO5700746A2 (es) 2006-11-30
US7727985B2 (en) 2010-06-01
CR8042A (es) 2006-05-30
TNSN05257A1 (en) 2007-07-10
KR20060006031A (ko) 2006-01-18
CN1802375A (zh) 2006-07-12
BRPI0409263A (pt) 2006-03-28
NI200500174A (es) 2006-04-17
NO20054598D0 (no) 2005-10-06
CA2521300A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
MA27837A1 (fr) Beta-carbolines utiles pour traiter une maladie inflammatoire.
NL1028303A1 (nl) Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
DE602004019373D1 (de) Bilderzeugungsverfahren
NO20053860D0 (no) COP 1 for behandling av inflammatorisk tarmsykdom.
EP1941908A4 (en) THERAPEUTIC AGENT AGAINST HEART DISEASES
DE602005010597D1 (de) Bildaufzeichnungsverfahren
ZA200608955B (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
ZA200707498B (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
IL180721A0 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
ITRE20030089A1 (it) Gruppo autocentrante perfezionato.
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
EP1844158A4 (en) BIOMARKER FOR INFLAMMATORY ENDURANCE
EP1546308A4 (en) METHOD FOR TREATING AUTOIMMUNE DISEASE
EP2044957A4 (en) AGENT FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
EP2201372A4 (en) NEW THERAPEUTIC TARGET MOLECULES IN STOMACH DISEASES
EP1536000A4 (en) Method of judging inflammatory disease
EP1974732A4 (en) THERAPEUTIC AGENT AGAINST NEURODE GENERATIVE DISEASES
LU91032B1 (de) Mauerstein.
FR2858344B1 (fr) Bloc pour paroi bio climatique.
FI20030467A0 (fi) Menetelmä tulehdustilojen hoitamiseen
ITVI20060251A1 (it) Gruppo perfezionato per l'egorazione di acqua miscelata.
FR2858212B1 (fr) Cercueil en particulier pour la cremation
EP1667677A4 (en) COMPOSITION FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
ITTO20031040A1 (it) Gruppo cuscinetto mozzo-ruota per veicoli.
FR2858915B1 (fr) Rabatteur pour faucheusse-moissonneuse